The cellular immune response is accompanied by the release of neopterin. The level of neopterin in serum is increased in patients suffering from viral infections, autoimmune diseases, systemic inflammation, allograft rejection and malignant diseases, while that of C-reactive protein (CRP) is known to rise during inflammatory diseases and traumas. To investigate postmortem neopterin and CRP concentrations with regard to the cause of death, we examined cardiac and peripheral blood samples in 474 autopsy cases without advanced decomposition (0-96 years of age, 343 males and 131 females), 2.8 h to 3 days (median, 18.0 h) after death. Survival time was 0.1 h to 5 months (median, 3.0 h) for traumatic death, and 0.1-1, 440 h (median, 2.5 h) for natural death. In autopsied subjects, neopterin concentrations were higher than the clinical reference, independent of the time after death, and depended on the survival time. In cases of acute and subacute death due to trauma, the neopterin level in right heart blood was mildly to moderately elevated (about 50-200 nmol/l) except for sharp instrument injury, whereas the CRP concentration usually remained low (<1 mg/dl). However, a moderate rise in the CRP level (around 1-10 mg/dl) was observed in fatal cases of hypothermia (cold exposure). Markedly elevated serum CRP and neopterin levels (>10 mg/dl and >500 nmol/l, respectively) were detected in cases of delayed death due to trauma involving systemic inflammatory response syndrome (SIRS) and of fatal bacterial infections. For sepsis, the serum CRP level was markedly elevated but the neopterin level was low in some cases. Fatal viral infections usually resulted in a marked elevation in the serum neopterin level (>500 nmol/l) with a mild to moderate rise in the CRP level. Combined analyses of neopterin and CRP may be useful to investigate viral infections and delayed traumatic death involving SIRS to support pathological findings.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.forsciint.2008.04.021 | DOI Listing |
EBioMedicine
December 2024
Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Section for Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway. Electronic address:
Background: The Bari-SolidAct randomized controlled trial compared baricitinib with placebo in patients with severe COVID-19. A post hoc analysis revealed a higher incidence of serious adverse events (SAEs) among SARS-CoV-2-vaccinated participants who had received baricitinib. This sub-study aimed to investigate whether vaccination influences the safety profile of baricitinib in patients with severe COVID-19.
View Article and Find Full Text PDFArch Bone Jt Surg
January 2024
University of Health Sciences, Gulhane Faculty of Pharmacy, Department of Biochemistry, Ankara, Türkiye.
Objectives: In this study, the Kellgren and Lawrence system was used as the most common radiographic grading system for diagnosis of osteoarthritis in patients defined as Grade III and IV. It is aimed to reveal oxidative stress and cellular immunity status. In this context, the aim is to discuss possible risk parameters regarding disease process and treatment effectiveness.
View Article and Find Full Text PDFPol Merkur Lekarski
December 2024
UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE.
Objective: Aim: To study and analyze the treatment effectiveness in children with identified Coronavirus infection..
Patients And Methods: Materials and Methods: included the treatment and analysis of the study results of of children (n=68, aged 14.
Wiad Lek
December 2024
UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE.
Brain Behav Immun
November 2024
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm 17177, Sweden. Electronic address:
Long-term symptoms such as pain, fatigue, and cognitive impairments are commonly observed in individuals affected by coronavirus disease 2019 (COVID-19). Metabolites of the kynurenine pathway have been proposed to account for cognitive impairment in COVID-19 patients. Here, cerebrospinal fluid (CSF) and plasma levels of kynurenine pathway metabolites in 53 COVID-19 patients and 12 non-inflammatory neurological disease controls in Sweden were measured with an ultra-performance liquid chromatography-tandem mass spectrometry system (UPLC-MS/MS) and correlated with immunological markers and neurological markers.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!